| | | March 30, 2022 Welcome to the BRAND NEW Stock Dork Premarket Report, your go-to guide for the day's biggest trading news and hottest premarket stocks. Keep an eye out for our Premarket Reports moving forward and, as always, we invite you to reply to this email with your feedback, suggestions, or comments. It's Wednesday, March 30th. Let's get ready to trade! |
Stocks gained on Tuesday, with the Nasdaq's 1.8% gain leading the way. The S&P 500 rallied 1.2%, and the Dow added 1.0%. The small-cap Russell 2K index spiked 2.7% in the session. Today, rising oil prices are triggering declines ahead of the opening bell. S&P 500 contracts are currently showing a 0.3% loss. Micron [MU] - Last Close: $82.05 Micron is trending on an upbeat earnings report. The chipmaker reported better-than-expected fiscal Q2 adjusted earnings late Tuesday of $2.14 per diluted share, marking a sharp improvement from the year-earlier quarter's $0.98 per share earnings. Analysts expected EPS of $1.98 for the quarter.
Revenues came in at $7.79 billion, also topping the Wall Street target of $7.54 billion. The company's fiscal Q3 forecast of $8.5 billion to $8.9 billion also surpassed analysts' expectation of $8.16 billion. MU is leading the S&P 500 with a 4.0% gain. Adagio Therapeutics [ADGI] - Last Close: $3.85 Adagio Therapeutics is moving higher on upbeat clinical data. The clinical-stage biopharmaceutical company announced today that Phase 2/3 studies of its investigational antibody ADG20, or adintrevimab, met its primary endpoints as a potential COVID-19 treatment. Adagio said the trials tested ADG20 as a pre- and post-exposure prophylaxis and as a treatment for the disease. The trials showed the drug candidate produced a reduction in symptomatic cases of COVID-19 against placebo. The company said it plans to seek final approval from the US Food & Drug for emergency use of the drug in the second quarter for both prevention and treatment of COVID-19. ADGI is trading actively with a 71.4% gain in the premarket. Direct Digital Holdings [DRCT] - Last Close: $2.58 Upbeat earnings numbers are lifting shares of Direct Digital Holdings. The advertising platform operator reported significant revenues growth and better-than-expected guidance that surpassed Wall Street's expectations. Direct Digital said its fourth-quarter revenue grew by 95% YoY from $6.3 million to $12.9 million. The company reported a net loss of $2.1 million. The company expects Q1 revenues to come in between $11 million and $11.5 million, versus the Street's $8.42 million estimate. DRCT is trading actively in the premarket with a 34.5% gain. Vyant Bio Inc [VYNT] - Last Close: $1.35 Vyant Bio is soaring on a new clinical partnership. The biotech drug discovery company announced a new collaboration agreement with OrganoTherapeutics to develop drugs for the treatment of Parkinson's Disease. The companies didn't disclose specific details of the deal. According to an announcement, the companies will focus on identifying drug candidates that rescue the PD phenotype through developing disease-linked, clinically-translatable assays and biomarkers. The companies will integrate and utilize OrganoTherapeutic's "patient-derived, 3D-organoid disease models derived from induced pluripotent stem cells (iPSCs), Vyant Bio's iPSC expertise, and its AnalytiX machine learning technology." VYNT is up 25.2% on active premarket trading volume. |
| Gainers Sonoma Pharma [SNOA] >> +26.5% China SXT Pharma [SXTC] >> +13.2% Agile Thrpe [AGRX] >> +7.0% Decliners Calithera Bioscience [CALA] >> (33.1%) Stronghold Digital [SDIG] >> (29.4%) Geron Corp. [GERN] >> (18.0%) Five Below [FIVE] ... AM Paychex [PAYX] ... AM BioNTech [BNTX] ... AM Aercap [AER] ... AM Braze [BRZE] ... PM UiPath [PATH] ... PM |
| ADP Employment Report [Mar] ... 8:15a GDP Revision [Q4] ... 8:30a |
| Thanks for reading! Don't forget, I'm always eager to hear from you. Reply to this email with your questions, comments, or general feedback, and Ill get back to you as soon as I can. Wishing you big returns on your investments this week, as always! - Michael "The Dork" Taylor P.S. Want My Alerts Delivered To Your Cell Phone? Sign up for mobile alerts and get the latest updates delivered to your cell. Disclaimer © 2022 TheStockDork.com. All rights reserved. This message was sent by TheStockDork.com and may contain commercial elements such as advertising. Read full terms here. |
|
|
|
| | |
|
